Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study

Maeda, Osamu; Matsuoka, Ayumu; Miyahara, Ryoji; Funasaka, Kohei; Hirooka, Yoshiki; Fukaya, Masahide; Nagino, Masato; Kodera, Yasuhiro; Goto, Hidemi; Ando, Yumiko

doi:10.3748/wjg.v23.i6.1090

Cited by 8 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the silencing or overexpression of Rab23 induced the down-or upregulation of ABCG2 expression, respectively, at the mRNA and protein levels. DDP is one of the most commonly used chemotherapy drugs in multiple types of tumors, and functions by inducing cancer cell death via the activation of the DNA damage response, leading to cell cycle arrest and the induction of mitochondrial apoptosis (14,15). In OC, DDP is used as a first line chemotherapy drug (16).…”

Section: Discussionmentioning

confidence: 99%

Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway

Zhang

Feng²,

Wang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract.As a novel member of the Rab GTPase family, the role of Rab23 has been reported in multiple types of tumor. However, to the best of our knowledge, the role of Rab23 in ovarian cancer (OC) has not yet been reported. In the present study, immunohistochemistry analysis demonstrated that Rab23 was upregulated in OC tissue; survival analysis indicated that Rab23 expression was associated with a reduced overall survival (OS) rate and disease-free survival (DFS) time. In vitro experiments also demonstrated the increased expression of Rab23 in the OC cells lines, A2780 and SKOV-3, compared with in the normal ovarian cell line, IOSE80. Following the silencing of ABCG2 in SKOV-3 cells, ATP-binding cassette sub-family G member 2 (ABCG2) expression was significantly downregulated both at the RNA and protein levels. The cisplatin (DDP) IC 50 declined from 43.09±7.12 µmol/l in control cells to 26.46±5.38 µmol/l in SKOV-3 cells with silenced Rab23. In contrast, in A2780 cells overexpressing Rab23 (A2780-Rab23), ABCG2 expression was significantly upregulated and the DDP IC 50 increased from 27.42±6.54 µmol/l in control cells to 45.92±5.23 µmol/l in A2780-Rab23. Investigation into the potential molecular mechanisms for this revealed that the expression of sonic hedgehog (Shh) and Gli family zinc finger 1 (Gli1) was increased in A2780-Rab23 cells, whereas silencing Rab23 in SKOV-3 cells significantly inhibited the expression of Shh and Gli1. The Gli1 inhibitor GANT-61 significantly abrogated the increased ABCG2 expression in A2780-Rab23 cells. Furthermore, the DDP IC 50 in A2780-Rab23 cells decreased significantly following the silencing of ABCG2 expression; the IC 50 declined from 51.66±8.32 µmol/l in A2780-Rab23 cells to 25.61±6.17 µmol/l in A2780-Rab23 cells with silenced ABCG2. Collectively, the results indicate that Rab23 promotes the DDP resistance of OC cells via the Shh-Gli1-ABCG2 pathway, providing the proof of principle for the further investigation of drug resistance therapy targeting Rab23.

show abstract

Section: Discussionmentioning

confidence: 99%

Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway

Zhang

Feng²,

Wang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Additionally, rates of relatively severe postoperative complications between 24.2 and 40% (35, 40, 41, 48) make stringent selection of unresectable stage IV GC patients who may benefit from conversion surgery increasingly necessary. Criteria for conversion surgery included: no sign of organ failure, age between 20 and 80 years, Eastern Cooperative Oncology Group scale performance status 0–2, and one single incurable factor (41, 45). Moreover, modern diagnostic tools, such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography CT (PET-CT), upper gastrointestinal tract endoscopy, and ultrasonography, may help determine clinical staging before undertaking surgical intervention for GC patients (41, 42, 44).…”

Section: Future Work and Perspectivesmentioning

confidence: 99%

Conversion Surgery for Stage IV Gastric Cancer

et al. 2019

View full text Add to dashboard Cite

The prognosis of stage IV gastric cancer (GC) is poor, with palliative chemotherapy remaining the main therapeutic option. Studies increasingly indicate that patients with unresectable stage IV GC, who undergo gastrectomy with radical intention after responding to several regimens of combined chemotherapy, can achieve good survival outcomes. Thus, surgery aiming at radical resection for unresectable stage IV GC after combined chemotherapy has received increasing attention in recent years. This novel therapeutic strategy was defined as conversion surgery in patients with unresectable stage IV GC and it can associate with significant improved survival when R0 resection can be achieved. Despite the recent advances in conversion surgery for patients with unresectable stage IV GC, selection criteria for combination chemotherapy regimens, indications for conversion surgery, optimal timing to surgery, and postoperative chemotherapy all remain controversial. This article reviews the current state of conversion surgery for unresectable stage IV GC.

show abstract

“…DCX was reported to be used as neoadjuvant chemotherapy, which was administered before surgery for resectable diseases[12], and 63% of the patients achieved R0 resection. To maintain effectiveness and avoid severe adverse events, a modified DCX regimen in which docetaxel was reduced was reported[13]. With this regimen, three out of eight patients underwent conversion gastrectomy and achieved long-term survival.…”

Section: First-line Chemotherapy For Gastric Cancermentioning

confidence: 99%

Recent progress of chemotherapy and biomarkers for gastroesophageal cancer

Maeda

Ando

2019

WJGO

Self Cite

View full text Add to dashboard Cite

Key cytotoxic drugs of chemotherapy for gastroesophageal cancer include fluoropyrimidine, platinum, taxanes and irinotecan. Concurrent chemoradiotherapy is one of the main treatment strategies, especially for esophageal cancer. As molecular target agents, the anti-HER2 antibody trastuzumab for HER2-positive gastric cancer and the anti-angiogenesis agent ramucirumab combined with paclitaxel have been proven to improve the survival of gastric cancer patients. Recently, anti-PD-1 antibodies have become available as second- or later-line chemotherapy. Microsatellite instability is also useful as a biomarker to select patients suitable for immunotherapy. Furthermore, genome-wide analysis has improved our understanding of the biological features and molecular mechanisms of gastroesophageal cancer and will provide optimized treatment selection.

show abstract

Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study

Cited by 8 publications

References 17 publications

Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway

Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway

Conversion Surgery for Stage IV Gastric Cancer

Recent progress of chemotherapy and biomarkers for gastroesophageal cancer

Contact Info

Product

Resources

About